LXEO

+ Watchlist + Portfolio

Lexeo Therapeutics, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.62
52-Week Range: $2.98 – $10.99
Market Cap: $289.77M
P/E (TTM): —
EPS (TTM): -1.02
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.18
PEG Ratio: —
Return on Equity: -46.76%
Return on Assets: -27.59%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 13.89
Debt/Equity: 0.03
Total Debt: $6.81M
Free Cash Flow: $-58.79M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $84.72M

LXEO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$654.00K	$0.00	$0.00	$0.00
Research & Development	$49.16M	$53.13M	$74.09M	$63.80M
Selling, General & Admin	$12.00M	$15.38M	$31.68M	$45.46M
Operating Expenses	$61.16M	$68.51M	$105.77M	$109.26M
Operating Income	-$60.51M	-$68.51M	-$105.77M	-$109.26M
EBITDA	-$58.04M	-$64.35M	-$96.19M	-$97.68M
Pretax Income	-$59.28M	-$66.39M	-$98.33M	-$99.96M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$59.28M	-$66.39M	-$98.33M	-$99.96M
Diluted EPS	-2.36	-12.40	-3.09	-1.86
Diluted Shares	25.17M	5.35M	31.79M	53.65M

LXEO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$77.33M	$121.47M	$35.01M	$63.00M
Current Assets	$80.05M	$124.29M	$126.12M	$188.39M
Total Assets	$97.08M	$139.81M	$146.94M	$268.69M
Current Liabilities	$14.35M	$17.24M	$22.85M	$16.81M
Total Debt	$13.48M	$11.64M	$9.92M	$7.89M
Total Liabilities	$210.03M	$26.27M	$30.10M	$22.02M
Retained Earnings	-$115.45M	-$181.84M	-$280.17M	-$380.13M
Shareholders' Equity	-$112.95M	$113.53M	$116.84M	$246.67M
Working Capital	$65.70M	$107.06M	$103.28M	$171.58M

LXEO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$54.56M	-$59.50M	-$81.15M	-$98.56M
Capital Expenditure	-$901.00K	-$165.00K	-$481.00K	-$397.00K
Free Cash Flow	-$55.46M	-$59.66M	-$81.63M	-$98.96M
Depreciation & Amortisation	$1.15M	$1.84M	$2.00M	$2.08M
Stock-Based Compensation	$1.78M	$3.04M	$12.47M	$12.13M
Investing Cash Flow	-$901.00K	-$165.00K	-$94.08M	-$90.25M
Financing Cash Flow	$189.00K	$103.79M	$88.78M	$216.79M
Share Repurchases	—	$0.00	-$17.00K	$0.00
Net Change in Cash	-$55.27M	$44.13M	-$86.45M	$27.98M

LXEO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.17M	$14.72M	$15.70M	$16.21M	$15.70M	$19.03M
Selling, General & Admin	$16.63M	$15.97M	$5.95M	$6.91M	$6.63M	$8.99M
Operating Expenses	$33.80M	$30.69M	$21.65M	$23.12M	$22.33M	$28.02M
Operating Income	-$33.80M	-$30.69M	-$21.65M	-$23.12M	-$22.33M	-$28.02M
EBITDA	-$32.12M	-$25.53M	-$19.67M	-$20.36M	-$19.63M	-$25.28M
Pretax Income	-$32.66M	-$26.10M	-$20.28M	-$20.92M	-$20.20M	-$25.87M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$32.66M	-$26.10M	-$20.28M	-$20.92M	-$20.20M	-$25.87M
Diluted EPS	-0.99	-0.60	-0.33	-0.27	-0.25	-0.30
Diluted Shares	33.11M	43.57M	60.98M	76.36M	81.18M	85.63M

LXEO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$28.91M	$35.48M	$41.00M	$63.00M	$71.77M	$92.83M
Current Assets	$105.27M	$140.06M	$127.79M	$188.39M	$200.86M	$217.91M
Total Assets	$125.69M	$176.07M	$143.84M	$268.69M	$250.36M	$254.90M
Current Liabilities	$30.82M	$31.59M	$17.27M	$16.81M	$14.19M	$15.69M
Total Debt	$9.40M	$8.91M	$8.46M	$7.89M	$7.37M	$6.81M
Total Liabilities	$37.58M	$37.85M	$23.01M	$22.02M	$18.86M	$19.84M
Retained Earnings	-$312.83M	-$338.93M	-$359.21M	-$380.13M	-$400.33M	-$426.20M
Shareholders' Equity	$88.11M	$138.22M	$120.83M	$246.67M	$231.50M	$235.06M
Working Capital	$74.45M	$108.47M	$110.52M	$171.58M	$186.67M	$202.22M

LXEO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$21.72M	-$27.22M	-$29.55M	-$20.08M	-$21.14M	-$17.60M
Capital Expenditure	—	—	-$289.00K	—	-$35.00K	-$7.00K
Free Cash Flow	-$21.72M	-$27.33M	-$29.84M	-$20.08M	-$21.18M	-$17.60M
Depreciation & Amortisation	$501.00K	$510.00K	$530.00K	$538.00K	$546.00K	$556.00K
Stock-Based Compensation	$3.70M	$3.07M	$2.65M	$2.71M	$2.75M	$5.69M
Investing Cash Flow	$15.60M	-$39.17M	$35.01M	-$101.69M	$27.46M	$14.26M
Financing Cash Flow	$11.00K	$72.96M	$52.00K	$143.77M	$2.45M	$24.40M
Share Repurchases	—	—	$0.00	$0.00	—	—
Net Change in Cash	-$6.11M	$6.57M	$5.52M	$22.00M	$8.77M	$21.07M

Market Snapshot

About

Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for cardiovascular, central nervous system, and ocular diseases. The company utilizes adeno-associated virus (AAV) delivery platforms to address genetic disorders with significant unmet medical needs. Lexeo focuses on one-time therapeutic interventions that could provide long-term benefits to patients with inherited conditions.